ADVERTISEMENT

NAVIGATOR Steers Uncontrolled Asthma Toward Calmer Seas

Neil Osterweil   |   Conference Report   |   18 May 2022
ADVERTISEMENT

SAN FRANCISCO — Nearly half of all patients with severe, uncontrolled asthma who received a full course of the biologic agent tezepelumab (Tezspire) in the NAVIGATOR trial had a complete response to treatment at 1 year, results of a prespecified exploratory analysis indicated.

Among 471 patients assigned to tezepelumab who completed the...

          

January Challenge

Ends in 2d 14h
left
right

Topic Challenges

left
right